A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2

Project: Research project

Project Details

Description

A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Adenocarcinoma of the Pancreas who have failed or are intolerant to First-Line Chemotherapy
StatusFinished
Effective start/end date4/15/144/30/19

Funding

  • Incyte Corporation

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.